Cancer treatment methods based on tp53 mutation status and hypermutation status
AssigneeTakeda Pharmaceutical Company Limited
InventorsAkihiro OHASHI, Kenichi IWAI, Tadahiro NAMBU, Kazunori YAMANAKA, Kentaro OTAKE, Huifeng NIU, Hyunjin SHIN, Erik Michael KOENIG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods useful for determining whether to treat cancer in a patient, and treating cancer in a patient, by administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof.
Claims21
A method of determining whether to treat a patient having cancer with Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- comprising:
- determining a TP53 mutation status and a hypermutation status from one or more samples from the patient, and
- determining to treat the patient with a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof if the one or more samples (i) have the presence of TP53 mutation(s) and (ii) test negative for hypermutation.
A method of treating cancer comprising:
- determining a TP53 mutation status and a hypermutation status of one or more samples from a patient, and
- administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- to the patient if the one or more samples (i) have the presence of TP53 mutation(s) and (ii) test negative for hypermutation.
The method of 6 or 7, wherein the cancer is selected from squamous esophageal cancer and squamous non-small cell lung cancer.
A pharmaceutical composition comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- for use in treating cancer, wherein the cancer (i) has the presence of TP53 mutation(s) and (ii) tests negative for hypermutation.
A method of treating cancer comprising administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- to a patient in need thereof, wherein the cancer is selected from squamous esophageal cancer and squamous non-small cell lung cancer.
A pharmaceutical composition comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof
- for use in treating cancer, wherein the cancer is selected from squamous esophageal cancer and squamous non-small cell lung cancer.
Dependencies are inferred from the claim text.